Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 3,136 Shares

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $45,722.88. Following the sale, the chief financial officer now owns 315,045 shares of the company’s stock, valued at approximately $4,593,356.10. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $192,466.12.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $13.81 on Friday. The company’s 50-day moving average is $14.75 and its 200 day moving average is $10.95. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The company had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. On average, analysts predict that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently added to or reduced their stakes in LQDA. Fortitude Family Office LLC bought a new stake in shares of Liquidia during the fourth quarter valued at about $26,000. UBS Group AG increased its position in shares of Liquidia by 134.0% during the second quarter. UBS Group AG now owns 7,948 shares of the company’s stock valued at $35,000 after buying an additional 4,552 shares during the period. Legal & General Group Plc bought a new stake in shares of Liquidia during the second quarter valued at about $38,000. BNP Paribas Arbitrage SA increased its position in shares of Liquidia by 42.8% during the second quarter. BNP Paribas Arbitrage SA now owns 10,682 shares of the company’s stock valued at $47,000 after buying an additional 3,200 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Liquidia by 101.3% during the second quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock valued at $55,000 after buying an additional 3,524 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on LQDA. Bank of America lifted their price objective on shares of Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Liquidia in a report on Wednesday, April 10th. Wedbush reaffirmed an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a report on Thursday, December 21st. LADENBURG THALM/SH SH lifted their price objective on shares of Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, HC Wainwright lifted their price objective on shares of Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).